Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
Teradata Corp
TDC
5
Collegium Pharmaceutical
COLL
(FY)Dec 31, 2024 | (Q4)Dec 31, 2024 | (Q3)Sep 30, 2024 | (Q2)Jun 30, 2024 | (Q1)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q4)Dec 31, 2023 | (Q3)Sep 30, 2023 | (Q2)Jun 30, 2023 | (Q1)Mar 31, 2023 | |
---|---|---|---|---|---|---|---|---|---|---|
Total revenue | 4.31%598.03M | 32.14%50M | 9.54%182.05M | 6.77%190.24M | -8.05%175.74M | -24.76%573.32M | 201.05%37.84M | -30.31%166.19M | -35.06%178.17M | -19.21%191.12M |
Operating revenue | 4.31%598.03M | 32.14%50M | 9.54%182.05M | 6.77%190.24M | -8.05%175.74M | -24.76%573.32M | 201.05%37.84M | -30.31%166.19M | -35.06%178.17M | -19.21%191.12M |
Cost of revenue | -0.05%501.97M | 55.71%38.75M | 4.95%158.76M | -2.94%155.75M | -10.18%148.71M | -23.57%502.2M | -6.23%24.89M | -27.99%151.27M | -29.97%160.47M | -13.47%165.57M |
Gross profit | 35.05%96.06M | -13.15%11.25M | 56.10%23.29M | 94.83%34.49M | 5.76%27.03M | -32.19%71.13M | 192.71%12.95M | -47.47%14.92M | -60.87%17.7M | -43.50%25.55M |
Operating expense | -6.44%75.68M | 48.35%13.17M | -11.43%22.79M | -7.03%20.59M | -20.74%19.13M | -11.72%80.88M | -41.37%8.88M | 3.93%25.73M | -10.65%22.15M | -10.44%24.13M |
Selling and administrative expenses | -3.99%73.19M | 44.85%13.08M | -10.70%21.85M | -1.80%19.94M | -18.34%18.31M | -9.44%76.23M | -37.84%9.03M | 8.63%24.47M | -9.21%20.31M | -9.43%22.42M |
-General and administrative expense | -3.99%73.19M | 44.85%13.08M | -10.70%21.85M | -1.80%19.94M | -18.34%18.31M | -9.44%76.23M | -37.84%9.03M | 8.63%24.47M | -9.21%20.31M | -9.43%22.42M |
Research and development costs | -75.43%711K | 41.16%-283K | -40.18%475K | -87.86%167K | -70.79%352K | -45.63%2.89M | -202.78%-481K | -49.62%794K | -21.55%1.38M | -20.98%1.21M |
Depreciation amortization depletion | 1.14%1.78M | 13.23%368K | -0.65%462K | 4.09%483K | -7.75%464K | -17.23%1.76M | 128.87%325K | -28.79%465K | -30.33%464K | -24.13%503K |
-Depreciation and amortization | 1.14%1.78M | 13.23%368K | -0.65%462K | 4.09%483K | -7.75%464K | -17.23%1.76M | 128.87%325K | -28.79%465K | -30.33%464K | -24.13%503K |
Operating profit | 308.85%20.38M | -147.04%-1.92M | 104.66%504K | 412.55%13.9M | 455.49%7.9M | -173.55%-9.76M | 114.00%4.08M | -396.00%-10.81M | -121.74%-4.45M | -92.22%1.42M |
Net non-operating interest income expense | 26.16%-4.66M | 283.05%5.65M | -12.04%-3.48M | -42.33%-3.38M | -49.50%-3.46M | -52.52%-6.32M | 250.05%1.48M | -172.93%-3.11M | -92.38%-2.37M | -194.02%-2.31M |
Non-operating interest expense | -26.16%4.66M | -283.05%-5.65M | 12.04%3.48M | 42.33%3.38M | 49.50%3.46M | 52.52%6.32M | -250.05%-1.48M | 172.93%3.11M | 92.38%2.37M | 194.02%2.31M |
Other net income (expense) | 88.96%-14.84M | 79.02%-14.56M | 99.96%-22K | 101.57%243K | -336.49%-499K | -30,782.88%-134.39M | -56,781.97%-69.4M | -13,920.85%-49.77M | -1,377.57%-15.43M | 172.01%211K |
Special income (charges) | 89.50%-13.88M | 80.16%-13.3M | --0 | 99.48%-80K | -634.78%-507K | -21,160.77%-132.24M | -6,703,600.00%-67.04M | -9,945.05%-49.72M | -6,601.30%-15.41M | 66.01%-69K |
-Less:Impairment of capital assets | -61.96%13.27M | --13.27M | --0 | --0 | ---- | --34.89M | --0 | --19.48M | --15.41M | ---- |
-Less:Other special charges | ---- | ---- | ---- | ---- | ---- | --92.29M | --66.68M | --25.61M | ---- | ---- |
-Write off | -87.89%613K | -92.74%26K | --0 | --80K | 634.78%507K | 713.50%5.06M | 35,700.00%358K | 835.96%4.63M | --0 | 866.67%69K |
Other non- operating income (expenses) | 55.70%-952K | 46.50%-1.26M | 56.86%-22K | 1,715.00%323K | -97.14%8K | -302.74%-2.15M | -283.58%-2.36M | -136.43%-51K | -162.50%-20K | 411.11%280K |
Income before tax | 100.58%880K | 83.04%-10.83M | 95.29%-3M | 148.35%10.76M | 681.86%3.95M | -1,673.24%-150.47M | -111.28%-63.84M | -3,051.20%-63.69M | -208.95%-22.25M | -103.94%-678K |
Income tax | 99.68%-165K | 89.32%-3.74M | 107.12%948K | 159.08%1.97M | 98.49%657K | -1,598.11%-51.3M | -233.87%-34.99M | -1,282.84%-13.31M | -159.95%-3.33M | -57.46%331K |
Net income | 39.03%-64.57M | -104.26%-72.7M | 92.17%-3.95M | 146.46%8.79M | 425.87%3.29M | -472.18%-105.91M | -820.38%-35.59M | -4,977.06%-50.38M | -227.26%-18.92M | -106.14%-1.01M |
Net income continuous Operations | 101.05%1.05M | 75.43%-7.09M | 92.17%-3.95M | 146.46%8.79M | 425.87%3.29M | -887.96%-99.17M | -46.18%-28.85M | -4,977.06%-50.38M | -227.26%-18.92M | -106.14%-1.01M |
Net income discontinuous operations | -873.44%-65.61M | ---- | ---- | ---- | ---- | -142.47%-6.74M | ---- | ---- | ---- | ---- |
Minority interest income | ||||||||||
Net income attributable to the parent company | 39.03%-64.57M | -104.26%-72.7M | 92.17%-3.95M | 146.46%8.79M | 425.87%3.29M | -472.18%-105.91M | -820.38%-35.59M | -4,977.06%-50.38M | -227.26%-18.92M | -106.14%-1.01M |
Preferred stock dividends | ||||||||||
Other preferred stock dividends | ||||||||||
Net income attributable to common stockholders | 39.03%-64.57M | -104.26%-72.7M | 92.17%-3.95M | 146.46%8.79M | 425.87%3.29M | -472.18%-105.91M | -820.38%-35.59M | -4,977.06%-50.38M | -227.26%-18.92M | -106.14%-1.01M |
Basic earnings per share | 39.35%-1.88 | -103.85%-2.12 | 92.52%-0.11 | 146.43%0.26 | 433.33%0.1 | -469.05%-3.1 | -845.45%-1.04 | -5,000.00%-1.47 | -227.27%-0.56 | -106.12%-0.03 |
Diluted earnings per share | 39.35%-1.88 | -103.85%-2.12 | 92.52%-0.11 | 146.43%0.26 | 433.33%0.1 | -469.05%-3.1 | -845.45%-1.04 | -5,000.00%-1.47 | -227.27%-0.56 | -106.12%-0.03 |
Dividend per share | 0 | 0 | 0 | 0 | 0 | -48.00%0.26 | 0 | 0 | 8.33%0.13 | 8.33%0.13 |
Currency Unit | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD |
Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
Audit Opinions | Unqualified Opinion | -- | -- | -- | -- | Unqualified Opinion | -- | -- | -- | -- |